XJPX
7917
Market cap573mUSD
Jul 10, Last price
1,320.00JPY
1D
1.54%
1Q
-6.32%
Jan 2017
-54.65%
IPO
106.25%
Name
Fujimori Kogyo Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fujimori Kogyo Co., Ltd., founded in Tokyo, Japan, in 1914, is a global provider of diverse packaging materials, specialized medical and pharmaceutical packaging solutions, and advanced functional components. The company operates through its Life Science, Information Electronics, and Building Materials segments. Its product portfolio features sophisticated optoelectronic offerings, such as MASTACK TFB, a protective film designed for optical applications. The electronics division supplies various products, including MASTACK PC, a heat-resistant protective film; FILMBYNA, a versatile release film used in pharmaceutical patches, adhesive applications, and electronic substrates; CLEAN PACK systems for the secure transfer and transport of semiconductors and precision devices; and META-SEAL FILM, an adhesive film. For the life sciences and general packaging sectors, Fujimori Kogyo manufactures single-use bags essential for bio-pharmaceutical production and microbiological cultures, plant culture bags, and specialized packaging for medical instruments and pharmaceutical products. The company additionally offers PP packaging materials, chemical solution bags, convenient liquid sticks, sealant materials, film separators, and innovative double-structure aerosol systems. Furthermore, its comprehensive range of container solutions includes high-hermetic options, refillable self-standing pouches, collapsible liquid containers, plastic film-lined containers, single-use culture products, liquid-pouch packaging materials suitable for retort sterilization, pouches with a spout, drum liners, and large-capacity liquid transport containers. All these products are marketed under the ZACROS brand name.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||